DIFGEN PHARMS announced FDA approval on September 15, 2026, for the ANDA application #220657, entering a pathway likely to disrupt market supply and competitive pricing dynamics. Inclusion in the brand name’s approved list signals a new entrant in the vertical, poised to alter market share and earnings pressure for competitor manufacturers.